Image source: © 2025 Krish Capital Pty.Ltd

Highlights

  • Indivior has earned a consensus rating of "Buy" from five brokerages.
  • Analysts set an average 1-year target price of USD 17.75 for the stock.
  • Craig Hallum raised its price target from USD 15.00 to USD 22.00 in June.

Indivior (NASDAQ:INDV) has earned a consensus rating of "Buy" from the five brokerages that are presently covering the stock, according to Reuters. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is USD 17.75.

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.

INDV has been the topic of a number of research reports. Craig Hallum boosted their price objective on shares of Indivior from USD 15.00 to USD 22.00 and gave the stock a "buy" rating in a research report on Monday, June 30th. Jefferies Financial Group began coverage on shares of Indivior in a research note on Tuesday, July 22nd. They issued a "buy" rating and a USD 20.00 price target on the stock. Finally, Wall Street Zen upgraded shares of Indivior from a "buy" rating to a "strong-buy" rating in a research note on Saturday, June 21st.

Indivior last released its quarterly earnings results on Thursday, April 24th. The company reported USD 0.41 earnings per share for the quarter, topping analysts' consensus estimates of USD 0.22 by USD 0.19. The firm had revenue of USD 266.00 million during the quarter, compared to the consensus estimate of USD 240.13 million. Indivior had a negative return on equity of 97.29% and a negative net margin of 4.02%. On average, research analysts predict that Indivior will post 1.22 earnings per share for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Indivior by 16.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,820 shares of the company's stock valued at USD 71,000 after purchasing an additional 666 shares during the period. Acadian Asset Management LLC acquired a new position in Indivior during the first quarter worth approximately USD 6,328,000. Jane Street Group LLC raised its stake in Indivior by 2,597.9% in the first quarter. Jane Street Group LLC now owns 995,013 shares of the company's stock valued at USD 9,327,000 after buying an additional 958,132 shares during the period. CTC Alternative Strategies Ltd. acquired a new stake in shares of Indivior in the first quarter valued at approximately USD 96,000. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Indivior by 18.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company's stock worth USD 79,757,000 after acquiring an additional 1,299,425 shares during the period. Institutional investors and hedge funds own 60.33% of the company's stock.